Home - Products - Others - Other Targets - Melanotan (MT)-II

Melanotan (MT)-II

CAS No. 121062-08-6

Melanotan (MT)-II( —— )

Catalog No. M30023 CAS No. 121062-08-6

Melanotan (MT)-II, a synthetic melanocortin receptor agonist, is a synthetic analogue of the peptide hormone α-melanocyte-stimulating hormone (α-MSH).

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	39	In Stock
5MG	61	In Stock
10MG	90	In Stock
25MG	155	In Stock
50MG	245	In Stock
100MG	398	In Stock
200MG	579	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Melanotan (MT)-II
Note

Research use only, not for human use.
Brief Description

Melanotan (MT)-II, a synthetic melanocortin receptor agonist, is a synthetic analogue of the peptide hormone α-melanocyte-stimulating hormone (α-MSH).
Description

Melanotan (MT)-II, a synthetic melanocortin receptor agonist, is a synthetic analogue of the peptide hormone α-melanocyte-stimulating hormone (α-MSH).
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

——
Research Area

——
Indication

——

Chemical Information

CAS Number

121062-08-6
Formula Weight

1024.18
Molecular Formula

C50H69N15O9
Purity

>98% (HPLC)
Solubility

In Vitro:?H2O : 6.67 mg/mL (6.51 mM)
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

INDY

INDY is an ATP-competitive inhibitor of Dyrk1A and Dyrk1B with IC50s of 0.24 μM and 0.23 μM and a Ki of 0.18 μM for Dyrk1A ATP pocket, respectively.
Suritozole

Suritozole is a negative modulator at the gamma-aminobutyric acidA (GABAA) receptorSuritozole is a negative modulator at the gamma-aminobutyric acidA (GABAA) receptor that enhances cholinergic function, in attenuating spatial memory deficits after traumatic brain injury in the rat.
KRM-III

KRM-III is an orally active T cell antigen receptor (TCR) inhibitor with anti-inflammatory activity that potently inhibits TCR and myristate acetate/fosfomycin/ionomycin-induced NFAT nuclear factor activation and T cell proliferation, with an IC50 of approximately 5 μM.

Sign In Join Free